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The autoimmune thyroid diseases (AITDs) (Graves’ disease and Hashimoto’s thyroiditis) are complex genetic diseases which most
likely have more than 20 genes contributing to the clinical phenotypes. To date, the genes known to be contributing fall into two
categories: immune regulatory genes (including HLA, CTLA4, PTPN22, CD40, CD25, and FCRL3) and thyroid-speciﬁc genes (TG
and TSHR). However, none of these genes contribute more than a 4-fold increase in risk of developing one of these diseases,
and none of the polymorphisms discovered is essential for disease development. Hence, it appears that a variety of diﬀerent gene
interactions can combine to cause the same clinical disease pattern, but the contributing genes may diﬀer from patient to patient
and from population to population. Furthermore, this possible mechanism leaves open the powerful inﬂuence of the environment
and epigenetic modiﬁcations of gene expression. For the clinician, this means that genetic proﬁling of such patients is unlikely to
be fruitful in the near future.
1.Introduction
Many diseases have a tendency to run in families, and
we know that this may be due to either environmental
inﬂuences, or family genetics, or both. The autoimmune
thyroid diseases (AITDs), Graves’ disease and Hashimoto’s
thyroiditis, are typical examples of such complex diseases
and have been recognized for many years as having an
important genetic component. In the last 10 years we have
learned many new insights into the way genetic inﬂuences
can enhance thyroid autoimmunity, but there remain large
gaps in our knowledge which are unlikely to be ﬁlled without
major theoretical and technical advances. This brief review
examines the current state of knowledge and what new
insights we have gained from exploring the genetics of the
AITDs, and in particular Graves’ disease.
2. Thyroid Autoantibodies
Autoantibodies to thyroid peroxidase (TPO) and thyroglob-
ulin (Tg) are reﬂections of thyroid disease rather than
causative agents [1]. Hence, such thyroid autoantibodies
may develop before the onset of clinical AITD and have
been long known to increase the risk of developing clinical
AITD [2]. The recognition of a familial association for the
production of thyroid antibodies [3] led to studies of ﬁrst-
degree relatives of probands with AITD and indicated a
dominant pattern of inheritance. Indeed, up to 50% of the
siblings of patients with AITD are thyroid antibody positive
[4, 5]i nc o n t r a s tt o∼15% in the general population [6].
Several segregation analyses have also shown a Mendelian
dominant pattern of inheritance for the expression of
thyroid autoantibodies [7, 8], and genetic transmission of
TPO antibody subclass “ﬁngerprints” has suggested that the
pattern of autoantibody recognition of the TPO antigen was
also genetically transmitted [9].
3.GeneticSusceptibilityto AITD
The recognition of an association between AITD and
certain human leukocyte antigens (HLA) ﬁrst provided a
mechanism for the genetic contribution to Graves’ disease
and Hashimoto’s thyroiditis [10]. This association has been
especiallywellseeninidenticaltwins[11].TheHLAantigens
provide a means for the immune system to recognize thyroid
antigenic peptides, and recent data have demonstrated
this enhanced association as secondary to the presence of
particular residues in the HLA class II binding pocket such as
Arg 74 [12]. In addition, as the pathological and molecular2 Journal of Thyroid Research
Table 1: Methods of genetic analysis.
(A) Linkage analysis
This is based on the principle that the chance for a
recombination event between 2 loci (i.e., a marker, such as the
candidate gene, and the true disease gene) is proportional to the
chromosomal distance between them. Therefore, if a marker is
close to a disease susceptibility gene, this marker will
cosegregate with the disease in families.
The logarithm of odds (LOD) score is a measure of the evidence
for or against linkage between a marker and a trait or disease
[13]. LOD score analysis has had important advantages for the
study of AITD because it has allowed a way to test for the
presence of heterogeneity within the data set and allowed
deduction of the mode of inheritance and the degree of
penetrance from the linkage data.
Linkage studies are highly speciﬁc but have been clearly shown
not to be highly sensitive.
(B) Association studies
These studies simply compare the presence of a disease marker
(such as the candidate gene) in the disease population with the
presence of the marker in a control population without the
disease.
Here, the diﬃculty may lie in the appropriate control
population, which needs to be comparable and large.
If this diﬃculty is overcome, association studies can reveal a
genetic inﬂuence, and with large patient groups, this type of
study can be highly sensitive.
mechanisms involved in AITD became known, many of
which were not only common to all autoimmune diseases
but also highly variable between individuals; this allowed
the recognition of candidate genes responsible for disease
susceptibility. Such genes could then be assessed by either
linkage analysis or association studies (see Table 1).
4.DetectingSusceptibilityGenesinAITD
The candidate HLA gene complex was ﬁrst associated with
AITD in association studies but then failed to show linkage
with AITD [14]. This showed that the genetic contribution
o fH L At oA I T Dw a sn o ts t r o n ge n o u g ht ob es e e ni n
linkage analyses [13]. This indicated that association studies
were more likely to detect genes contributing small eﬀects
on disease susceptibility. As a consequence of the Human
Genome Project, it became possible to identify genes for
diseasesthathadacomplexgeneticbasiswithoutresortingto
the candidate gene approach. This was achieved by “typing”
individuals using a genome screen of genetic markers, at ﬁrst
with microsatellites (1 microsatellite per 10cM DNA) and
later single-nucleotide polymorphisms (SNPs) (∼1S N Pp e r
< 1cM DNA), which covered the entire genome (Table 2)
[15]. Then investigators observed which markers segregated
with the disease. However, the reduced sensitivity of linkage
analyses, compared to association studies, made it more
diﬃcult to perform these analyses for the complex traits
characteristic of a non-Mendelian pattern of inheritance
and with variable clinical phenotypes. However, using large
Table 2: Methods for whole-genome screening.
(A) Microsatellites
These are regions in the genome that are composed of repetitive
sequences. The most common microsatellites are the CA
(dC-dA)n repeats. Microsatellite loci are highly polymorphic
because of variation in the number of repeats (usually there are
5 to 15 alleles per locus), and they are uniformly distributed
throughout the genome at distances of fewer than 1 million base
pairs [15]. Therefore, microsatellites served as useful markers in
linkage studies designed to search for unknown disease
susceptibility genes. Investigators then further narrowed the
suspected gene region with more dense markers, and the gene
could be identiﬁed.
(B) Single-nucleotide polymorphisms (SNPs)
Without having to enlist families, it is now possible to use
genome-wide association studies involving up to 106 SNPs (on a
microchip), each of which is in linkage disequilibrium with
large segments of the genome, and then analyze their
association with any disease.
numbers of SNPs, developed as a result of the HapMap
project [16, 17], and which had a much greater degree of
coverage of the whole genome, it was easier to decipher
which markers segregated with the disease using association
analyses. These SNP markers occur more frequently than
microsatellite markers and are easy to detect, allowing for
greater genetic sensitivity. The suspected gene region can
then be further narrowed with more dense SNPs and the
gene can be identiﬁed. Results are now available for a variety
of autoimmune diseases including rheumatoid arthritis and
type 1 diabetes mellitus [18] and most recently for AITD
[19].
It is obviously essential that whole-genome association
study results must be reliably and repeatedly reproduced,
but the complexity of this type of analysis and the high
cost have raised problems [20, 21]. If common diseases
are associated with common risks, then replication across
populations can be expected. But common diseases may
be related to population-speciﬁc risks, and, therefore, such




has persisted in the much larger studies using whole-genome
association studies such as in those analyzing Parkinson’s
disease and also obesity. Hence, all reports of genetic linkage
and association require conﬁrmation by independent studies
before they can be accepted.
5. Genes for AITD
The HLA and CTLA4 genes were the ﬁrst genes identiﬁed by
the candidate approach [22, 23]( T a b l e3).
As discussed earlier, the HLA genes make up the major
histocompatibility complex (MHC) which contains many
genes related to immune system function in humans. These
include HLA class I (A, B, and C), HLA class II (DP, DM,
DOA, DOB, DQ, and DR), and HLA class III (coding forJournal of Thyroid Research 3
Table 3: Genes linked and/or associated with autoimmune thyroid disease.
Gene symbol Gene name Chromosome location Odds ratio
HLA Major histocompatibility complex 6p21 2.0–4.0
CTLA4 Cytotoxic T-lymphocyte-associated protein 4 2q33 1.5–2.2
PTPN22 Protein tyrosine phosphatase, non-receptor type 22 (lymphoid) 1p13 1.4–1.9
CD40 CD40 molecule, TNF receptor superfamily member 5 20q11 1.3–1.8
IL2RA (CD25) Interleukin 2 receptor, alpha 10p15 1.1–1.4
FCRL3 Fc receptor-like 3 1q23 1.1–1.3
TG Thyroglobulin 8q24 1.3–1.6
TSHR Thyroid-stimulating hormone receptor 14q31 1.4–2.6
other immune proteins). The major GD-associated HLA,
HLA-DR3, locates at the HLA DR locus and plays a key role
in the normal immune response by binding peptide antigens
and presenting them to T-cell receptors.
The cytotoxic T-lymphocyte-associated protein 4 (CTL
A4) gene is an immune regulatory molecule, which is
expressed on the surface of Helper T cells and transmits
an inhibitory signal to T cells. In addition to the HLA and
CTLA4 gene loci, there are conﬁrmed associations (2 or
more reports) for a number of genes also common to many
autoimmune diseases: PTPN22, CD40, IL2RA (CD25), and
FCRL3 (Table 3).
The gene for protein tyrosine phosphatase, non-receptor
type 22 (lymphoid), also known as just PTPN22,e n c o d e s
a protein tyrosine phosphatase expressed primarily in lym-
phoid tissues. This enzyme associates with the molecular
adapter protein CBL and may be involved in regulating CBL
functionintheT-cellreceptorsignalingpathway.Avariantof
the PTPN22 encodes Lyp phosphatase (Lyp620W) and con-
fers risk for multiple autoimmune diseases. Most recently,
Zhang et al. [24] reported that levels of the Lyp620W variant
were decreased in human T and B cells, and its calpain
binding and cleavage were increased relative to wild-type
Lyp620R. Therefore, calpain-mediated degradation with
consequently reduced Lyp expression and lymphocyte and
dendritic cell hyperresponsiveness represents a potential
mechanism for unregulated autoimmunity. The LypR620W
variant, with an arginine to tryptophan substitution, loses
its function and inﬂuence on immune responses, which
increases the risk for autoimmune disease.
The CD40 molecule, or TNF receptor superfamily mem-
ber 5 gene, encodes a costimulatory receptor which is essen-
tial in mediating a broad variety of immune and inﬂamma-
tory responses including T-cell-dependent immunoglobulin
class switching, memory B-cell development, and germinal
center formation [25]. The interleukin 2 (IL2) receptor alpha
gene (IL2RA or CD25) encodes one of the subunits of the IL-
2 receptor that binds IL-2 and is vital in the regulation of T-
cell function. The Fc receptor-like protein 3 (FCRL3)g e n e
encodes a protein containing an immunoreceptor-tyrosine
activation motif and immunoreceptor-tyrosine inhibitory
motif in its cytoplasmic domain and may play a role in
immune regulation.
To date, the only thyroid-related genes associated with
AITDareTG (thegeneencodingthyroglobulin)[26],inboth
Graves’ disease and Hashimoto’s thyroiditis, and TSHR (the
gene encoding the thyrotropin receptor) restricted to Graves’
disease [27, 28]( T a b l e3).
The thyroglobulin (TG)g e n ee n c o d e sal a r g eg l y c o -
protein homodimer produced exclusively by the thyroid
gland. It acts as a substrate for the synthesis of thyroid
hormones thyroxine (T4) and triiodothyronine (T3) as well
as the storage of the inactive forms of thyroid hormone and
iodine. How this gene inﬂuences susceptibility is unclear but
Stefan et al. [29] have recently described a genetic/epigenetic
mechanism by which a newly identiﬁed TG promoter SNP
variant predisposes to AITD. Sequencing analyses followed
by case control and family-based association studies iden-
tiﬁed a SNP (−1623A→G) that was associated with AITD
in the Caucasian population, and the associated nucleotide
substitution SNP (−1623A/G) modiﬁed a binding site for
interferon regulatory factor-1 (IRF-1), a major interferon-
induced transcription factor, indicating enhanced sensitivity
to this inﬂammatory cytokine [29].
The thyroid stimulating hormone receptor (TSHR)g e n e
encodes a membrane protein that signals through binding
TSH ligand and is a major controller of thyroid cell growth
andmetabolism.SNPsinintron1(inCaucasians)andintron
7 (in Japanese) have been associated with Graves’ disease
in a number of studies [27, 28, 30]. Recent data suggest
that TSHR-associated SNPs are related to defective thymic
tolerance for the TSHR as shown by reduced expression
within the thymus gland where it is needed to delete TSHR
autoreactive T cells [31].
Because all the identiﬁed susceptibility genes found to
date appear to have a low level of contribution to genetic
susceptibility, a number of whole-genome screening studies
have also been attempted in AITD to ﬁnd more important
genes [32–36]. One whole-genome association study using
only 104 nonsynonymous SNPs (those involving parts of a
gene likely to aﬀect the product character) showed a number
of the previously recognized genes, as well as locating some
new sites, but the new sites could not subsequently be
conﬁrmed [37, 38]. Most recently, the ﬁrst full genome-
wide study of Graves’ disease with 660K SNPs has now
been reported from China [19]. This study again identiﬁed
many of the known genes for AITD, but also described two
new sites on chromosomes 6q and 4p. These await further
conﬁrmation. Again, however, no very highly associated new
g e n e sh a v ee m e r g e d .4 Journal of Thyroid Research
6.TheDegreeofEnhancedSusceptibility
Remains Low
All the genes associated with AITD are individually able
to confer only modest degrees of disease susceptibility
(expressed as odds ratios, see Table 3). Hence, these data
only allow us to conclude that the AITDs, both Graves’ dis-
ease (including Graves’ ophthalmopathy) and Hashimoto’s
thyroiditis, are complex genetic disorders involving multiple
genes that may interact to provide a susceptible background
for disease development. Furthermore, there appear to be
disease-speciﬁc genes, such as the gene encoding the TSHR
in Graves’ disease and a larger group of susceptibility genes,
such as CTLA4, which are common to many autoimmune
diseases. This combination of gene polymorphisms likely
allows epigenetic phenomena, subsequent to a variety of
inﬂuences such as infection and the environment, to initiate
disease.
7. The Controversy over Major Genesin AITD
After the clariﬁcation that multiple genes are at work in
AITD,itislikelythatmorethan20potentialgenescontribute
to the AITD phenotypes. But major genes, those essential
to disease development, have not been found [39]. A major
gene should be involved in the majority of patients with
the disease, and the risk ratios, even for HLA, do not
reveal such a gene (Table 3). This most likely means that
diﬀerent combinations of genes may produce similar clinical
phenotypes or that epigenetic phenomena are dominant.
So far, in the whole-genome screening of families, siblings,
and populations with AITD, a number of sites have been
established for Graves’ disease and Hashimoto’s thyroiditis
susceptibility, but none of them have had very high statistical
values (LOD scores) [32, 33, 35]. This ﬁnding has been true
not just for AITD, but also for other autoimmune diseases
including type 1 diabetes mellitus. This is best understood by
thinking of HLA once again. Not every patient with Graves’
disease has the associated HLA-DR3 subtype and not even
the associated Arg74 in its binding pocket, irrespective of the
HLA-DR subtype [12]. Hence, the disease can occur in the
absence of the expected HLA association.
8 .AN o t eo nE p ig e n etic s
One mechanism by which environmental factors may com-
bine with genetic risk to promote AITD is by altering the
epigenetic control of gene expression as seen, for example,
in the pancreas [40] and as shown for a virus interacting
with a susceptibility gene in Crohn’s disease [41]. While
little is known about such interactions with AITD, there
has been wide conﬁrmation of a role for X chromosome
inactivation (XCI) [42, 43]. Patients with AITD more often
than expected showed a biased expression of a maternal
or paternal X chromosome leading to the hypothesis that
the poorly expressed chromosome could become active in
certain tissues such as the thyroid and express new antigenic
sequences not previously recognized by the immune system.
These potential mechanisms for enhanced susceptibility to
AITD require further exploration.
9. Conclusions
How environmental factors combine with genetic risk at the
molecular level to promote complex genetic diseases such
as AITD is largely unknown. The genes that are linked to
and/or associated with AITD are each small contributors to
genetic risk. Multiple-gene polymorphisms (combinations
of haplotypes) appear to be needed to develop AITD and
may diﬀer between geographic populations secondary to
epigenetic inﬂuences. Much remains to be learned.
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